Dyax HAE Allies? Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day - a Global

Before you go, we thought you'd like these...
Before you go close icon

Dyax HAE Allies℠Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day - a Global Event to Raise Awareness of HAE

New program acknowledges critical role of support for patients with rare and potentially life-threatening disease

BURLINGTON, Mass.--(BUSINESS WIRE)-- To mark the second annual Hereditary Angioedema (HAE) Day, Dyax Corp. today announced the launch of HAE Allies, a new program recognizing the physicians, nurses, family members and friends who support HAE patients in their efforts to live life to the fullest. By drawing from the inspiring stories of individual HAE patient allies nationwide, the programseeks to underscore the value of support for those living with this potentially life-threatening condition, which is characterized by spontaneous episodes of edema, or swelling, in the face, feet, hands, throat, and abdomen.


HAE Allies is asking HAE patients across the country to nominate the people in their lives who provide the support which enables them to better manage their condition, to achieve their personal and professional goals, or cope with the unpredictability of HAE. Nomination forms can be found on www.HAEHope.com, a support website sponsored by Dyax, the marketer of KALBITOR® (ecallantide) for the treatment of sudden attacks of HAE in patients 16 years of age and older. For each submission, Dyax will donate $25 to the US Hereditary Angioedema Association (HAEA) — the largest HAE patient group in the country. Program submissions will be used in the development of support services and educational materials for HAE patients nationwide. A multi-disciplinary council consisting of physicians, nurses, patients and advocacy representatives will evaluate each submission and select five honorees to be recognized at the HAEA Patient Summit in Orlando, Florida on September 27, 2013. A donation of $250.00 will be made in the honoree's name to the HAE advocacy organization of their choice.

"I've heard so many compelling stories of people with HAE pursuing goals that would have been unimaginable just a few short years ago, before today's novel treatments and services were available," stated Jill Searchinger, RN. "Time and time again, the support network is central to these individuals achieving their goals - whether it is a spouse who pitches in with household chores, a nurse who administers medication or a neighbor who brings their children to school during an HAE attack."

Although HAE can be diagnosed through a simple blood test, the disease is frequently undetected or misdiagnosed due to its rarity and the similarity of its symptoms to more common conditions. In the spirit of HAE Day, HAE Allies seeks to raise awareness of this little known condition and honor those individuals who support people living with HAE.

"At Dyax, we work closely with HAE patients to understand not only how this condition affects their lives but how our support services can be tailored to help meet their unique needs and assist in the management of their condition," stated Gustav Christensen, President and Chief Executive Officer of Dyax. "While many individuals are getting the support they need, many others are not. With HAE Allies, we hope to inspire those others with success stories of individuals whose close partnership with their healthcare professionals has allowed them to effectively manage their condition and surround themselves with a community they can rely on when in need."

About HAE Day

Last year, the United States Senate passed a resolution recognizing May 16 as HAE Day. The HAE Day aims to raise awareness of hereditary angioedema (HAE) among the general public and medical community, in an effort to promote better care and earlier, more accurate, diagnosis as well as the knowledge that HAE patients can lead a healthy life. This event was initiated by the HAEi, the International Patient Organization for C1-Inhibitor Deficiencies, along with the support of its National Member Organizations. For more information about HAE Day, please visit www.haeday.org.

About HAE

Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect up to 1 in 50,000 individuals. Learn more at www.HAEHope.com/HAEAllies.

About KALBITOR®(ecallantide)

KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR, which was discovered and developed by Dyax, was the first subcutaneous treatment available in the U.S. for treating acute HAE attacks.

For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.

The Company is currently developing products to expand its angioedema portfolio, including a suite of diagnostic assays to identify plasma kallikrein-mediated (PKM) angioedemas and a therapeutic candidate, DX-2930, for the prophylactic treatment of HAE.

KALBITOR and DX-2930 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 13 revenue generating product candidates in various stages of clinical development, including three in Phase 3 trials.

For additional information about Dyax, please visit www.dyax.com.

Disclaimer

This press release contains forward-looking statements. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect future performance include the risks that: KALBITOR and/or DX-2930 may face competition from other products that are developed and/or marketed to treat HAE; KALBITOR and/or DX-2930 may not gain market acceptance; Dyax is dependent on the expertise, effort, priorities and contractual obligations of third parties in the manufacture, marketing, sales and distribution of KALBITOR and DX-2930; and other risk factors described or referred to in Item 1A, "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.

HAE Allies is a service mark of Dyax Corp. Dyax, the Dyax logo and KALBITOR are registered marks of Dyax Corp.



Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director,
Investor Relations and Corporate Communications
jrobinson@dyax.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article Dyax HAE Allies℠ Awards Program Launches on Second Annual Hereditary Angioedema (HAE) Day - a Global Event to Raise Awareness of HAE originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners